Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CapsoVision Q3 2026 Results: Net Loss of $7.34M, Loss Narrows

CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.63.5
Gross profit1.81.9
Profit before tax-7.3-7.9
Net income-7.3-7.9
EPS (diluted, $ a share)$-0.15$-0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+0.8%
Gross margin49.4%
Operating margin-207.0%
Source

10-Q filed with the SEC, NASDAQ: CV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CapsoVision, Inc: key numbers

Share price
$6.47Close, Nov 16
Market cap
$347M
Shares outstanding
53.61MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CapsoVision, Inc

All →
4:35 PM ET 8-K
Financial Results

CapsoVision Financial Results

CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.

Term
Q3 2026

“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”

Johnny Wang, President and Chief Executive Officer

“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”

Johnny Wang, President and Chief Executive Officer
11:08 AM ET 8-K
Regulatory Approval

CapsoVision Regulatory Approval

CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.

5:48 AM ET Form 4
Insider Buying

CapsoVision Insider Eliyahou Et Al Harari Buys $10M of Stock

Eliyahou Et Al Harari bought 1,757,469 shares of CapsoVision, Inc at $5.69 a share, worth $10M in total on Sep 18, 2026. Shares held after the trade: 878,734.

Value
$10M
Shares
1,757,469
Average price
$5.69
Trade date
Sep 18, 2026
6:15 PM ET Form 4
Insider Buying

CapsoVision Insider Ching Hang Shen Buys $5M of Stock

Ching Hang Shen bought 878,734 shares of CapsoVision, Inc at $5.69 a share, worth $5M in total on Sep 15, 2026. Shares held after the trade: 2,926,655 (+42.9%).

Value
$5M
Shares
878,734
Price
$5.69
Holding change
+42.9%
Trade date
Sep 15, 2026
4:09 PM ET 8-K
Capital Raise

CapsoVision Capital Raise of $18M

CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share. The offering raised approximately $18 million in gross proceeds from existing stockholders, including major investors Star One Global Capital Limited and Eliyahou Harari. The company intends to use the proceeds for general corporate purposes, including R&D and sales and marketing.

Value
$18M
Counterparty
Star One Global Capital Limited and Eliyahou Harari

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.